Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals - CNBC
Key takeaway
Novartis signs a licensing deal with Abogen Biosciences worth up to $7.8bn, targeting pipeline replenishment ahead of patent expirations.
- Step 1 · The triggerNovartis commits up to $7.8bn in licensing payments to Abogen Biosciences, transferring capital and validating Abogen's platform.
- Step 2 · Knock-onNovartis gains access to new pipeline candidates, offsetting upcoming patent expirations and raising the bar for external innovation sourcing.
- Step 3 · Knock-onThe high-value deal sets a new benchmark for Chinese biotech licensing, increasing expected valuations and competition for similar assets.
- Step 4 · Reaches youUS SMEs in pharma supply, research, or contract services face tighter procurement terms and higher input costs as Big Pharma intensifies external sourcing.
The trigger is reported by the source below. The steps that follow are Branch²’s traced reasoning — how the shock could reach a business like yours, not a prediction.
Source: Google News CNBC
See what today’s news does to your business. Atri by Branch² — Early-warning intelligence for your businessThis is automated analysis for information only. It is not investment advice, not a recommendation, and not a solicitation to buy or sell any security. Branch² is not authorised or regulated. Do your own research.